sucrose 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4610 57-50-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sucrose
  • cane sugar
  • saccharose
  • D-Sucrose
A nonreducing disaccharide composed of GLUCOSE and FRUCTOSE linked via their anomeric carbons. It is obtained commercially from SUGARCANE, sugar beet (BETA VULGARIS), and other plants and used extensively as a food and a sweetener.
  • Molecular weight: 342.30
  • Formula: C12H22O11
  • CLOGP: -3.09
  • LIPINSKI: 2
  • HAC: 11
  • HDO: 8
  • TPSA: 189.53
  • ALOGS: 0.38
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK1,NTRK2,PDK2,PDK4,PIK3CD,PRKDC,SIK2,STK33,TEK 25
kinase-selectivity-class ACVRL1,AXL,CDK1,CDK2,CDK4,CHUK,IRAK4,MAP2K6,MAP3K14,PDK1,PIK3CD,ZAP70 12
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product dose omission issue 29.13 21.21 37 2342 291650 90334418

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 172.89 30.67 58 3466 13398 42604413
Appendicitis 152.29 30.67 59 3465 20554 42597257
Blood phosphorus increased 122.26 30.67 44 3480 12481 42605330
Ventricular fibrillation 121.22 30.67 56 3468 30067 42587744
Cardiogenic shock 109.30 30.67 55 3469 35585 42582226
Myasthenia gravis 107.91 30.67 43 3481 16094 42601717
Abdominal distension 104.35 30.67 68 3456 71667 42546144
Ascites 100.68 30.67 61 3463 56617 42561194
Blood uric acid increased 99.01 30.67 40 3484 15507 42602304
Stress 98.14 30.67 55 3469 44157 42573654
Dry mouth 92.30 30.67 51 3473 39828 42577983
Blood cholesterol increased 75.34 30.67 39 3485 26702 42591109
Hyperphosphataemia 71.06 30.67 30 3494 12974 42604837
Incorrect route of product administration 64.32 30.67 34 3490 24271 42593540
Multiple organ dysfunction syndrome 63.13 30.67 57 3467 96978 42520833
Abdominal pain 63.10 30.67 78 3446 190393 42427418
Hyponatraemia 62.89 30.67 58 3466 101404 42516407
Neuralgia 59.84 30.67 33 3491 25614 42592197
Constipation 54.57 30.67 67 3457 162224 42455587
Hypophosphataemia 54.56 30.67 29 3495 20916 42596895
General physical health deterioration 51.74 30.67 63 3461 151183 42466628
Swelling 45.33 30.67 37 3487 54848 42562963
Bacteroides infection 44.78 30.67 14 3510 2573 42615238
Sleep disorder therapy 44.76 30.67 18 3506 6876 42610935
Bacterial infection 44.32 30.67 28 3496 27851 42589960
Sleep disorder 43.07 30.67 34 3490 48061 42569750
Analgesic therapy 42.24 30.67 17 3507 6507 42611304
Somnolence 39.13 30.67 53 3471 141052 42476759
Aortic stenosis 37.44 30.67 17 3507 8728 42609083
Total lung capacity decreased 36.53 30.67 13 3511 3557 42614254
Diabetes mellitus 36.48 30.67 34 3490 60053 42557758
Thrombosis 36.37 30.67 36 3488 68475 42549336
Drug therapy 35.77 30.67 15 3509 6365 42611446
Chronic obstructive pulmonary disease 33.19 30.67 33 3491 63081 42554730
Activated partial thromboplastin time prolonged 33.10 30.67 19 3505 15884 42601927
Ulcer 32.52 30.67 19 3505 16422 42601389
Intentional product misuse 31.88 30.67 32 3492 61868 42555943

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 199.11 21.76 58 5381 14197 110569663
Appendicitis 163.43 21.76 59 5380 28405 110555455
Ventricular fibrillation 132.02 21.76 56 5383 41257 110542603
Blood phosphorus increased 129.10 21.76 43 5396 16297 110567563
Myasthenia gravis 121.25 21.76 44 5395 21467 110562393
Cardiogenic shock 111.45 21.76 55 5384 57283 110526577
Blood uric acid increased 106.47 21.76 40 5399 21489 110562371
Abdominal distension 100.73 21.76 77 5362 175026 110408834
Ascites 99.41 21.76 60 5379 92748 110491112
Stress 92.42 21.76 60 5379 105288 110478572
Hyperphosphataemia 79.40 21.76 30 5409 16351 110567509
Neuralgia 69.71 21.76 38 5401 48440 110535420
Multiple organ dysfunction syndrome 66.59 21.76 57 5382 151653 110432207
Abdominal pain 59.34 21.76 97 5342 512892 110070968
Constipation 59.10 21.76 80 5359 357706 110226154
Hypophosphataemia 56.15 21.76 29 5410 33153 110550707
Incorrect route of product administration 54.94 21.76 36 5403 64025 110519835
Sleep disorder therapy 52.44 21.76 18 5421 7453 110576407
Dry mouth 51.44 21.76 56 5383 199892 110383968
Hyponatraemia 50.92 21.76 58 5381 217595 110366265
Bacteroides infection 50.28 21.76 14 5425 2905 110580955
Analgesic therapy 49 21.76 17 5422 7267 110576593
Thrombosis 48.00 21.76 41 5398 108621 110475239
Bacterial infection 47.28 21.76 29 5410 46007 110537853
Drug therapy 41.38 21.76 15 5424 7276 110576584
Diabetes mellitus 40.86 21.76 36 5403 99345 110484515
Aortic stenosis 39.36 21.76 17 5422 13042 110570818
Activated partial thromboplastin time prolonged 39.14 21.76 20 5419 22348 110561512
Chronic obstructive pulmonary disease 37.96 21.76 36 5403 109122 110474738
Somnolence 35.32 21.76 57 5382 297392 110286468
Sepsis 35.21 21.76 60 5379 327286 110256574
Total lung capacity decreased 34.36 21.76 13 5426 7101 110576759
End stage renal disease 31.32 21.76 17 5422 21456 110562404
Therapeutic reaction time decreased 30.48 21.76 11 5428 5268 110578592
Intentional product misuse 28.67 21.76 34 5405 132870 110450990
General physical health deterioration 28.66 21.76 64 5375 425231 110158629
Gout 27.62 21.76 19 5420 36547 110547313
Blood cholesterol increased 26.98 21.76 39 5400 184746 110399114
Anticoagulant therapy 26.63 21.76 10 5429 5351 110578509
Antacid therapy 26.41 21.76 10 5429 5474 110578386
Blood calcium increased 25.53 21.76 14 5425 18026 110565834
Testicular haemorrhage 25.00 21.76 5 5434 248 110583612
Sleep disorder 24.84 21.76 39 5400 198605 110385255
Ulcer 24.81 21.76 19 5420 43097 110540763
Troponin increased 23.75 21.76 16 5423 29750 110554110
Off label use 22.58 21.76 138 5301 1500047 109083813
Lung opacity 22.08 21.76 11 5428 11641 110572219

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D005421 Flavoring Agents
MeSH PA D005503 Food Additives
MeSH PA D013549 Sweetening Agents
CHEBI has role CHEBI:25728 osmolyte
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:50505 sweetening agent
CHEBI has role CHEBI:75771 mouse metabolite
CHEBI has role CHEBI:75772 <em>Saccharomyces cerevisiae </em> metabolite
CHEBI has role CHEBI:76971 <em>Escherichia coli</em> metabolite
CHEBI has role CHEBI:77746 human metabolite
CHEBI has role CHEBI:84735 algal metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.07 acidic
pKa2 13.11 acidic
pKa3 13.8 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D00025 KEGG_DRUG
4019358 VUID
N0000147528 NUI
4019358 VANDF
CHEBI:17992 CHEBI
SUC PDB_CHEM_ID
CHEMBL253582 ChEMBL_ID
5411 IUPHAR_LIGAND_ID
DB02772 DRUGBANK_ID
C151H8M554 UNII
10159 RXNORM
NOCODE MMSL
002598 NDDF
11320009 SNOMEDCT_US
9745007 SNOMEDCT_US
C0038636 UMLSCUI
D013395 MESH_DESCRIPTOR_UI
5988 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Select Brand Anti-Nausea HUMAN OTC DRUG LABEL 2 15127-291 SOLUTION 3.74 g ORAL unapproved drug other 11 sections
Emetrol Cherry HUMAN OTC DRUG LABEL 2 68788-9801 SOLUTION 3.74 g ORAL Unapproved drug other 13 sections
GZE GODDESS SUGAR SCRUB HUMAN OTC DRUG LABEL 1 74458-216 CAPSULE 15 g TOPICAL OTC Monograph Drug 10 sections
GZE GODDESS SUGAR SCRUB HUMAN OTC DRUG LABEL 1 74458-217 GRANULE 15 g TOPICAL OTC Monograph Drug 10 sections
AOAO Kojic Acid Whitening Lightener HUMAN OTC DRUG LABEL 6 84509-035 SOAP 1600 mg TOPICAL OTC Monograph Drug 9 sections
AOAO Kojic Acid Whitening Lightener HUMAN OTC DRUG LABEL 6 84509-049 SOAP 1600 mg TOPICAL OTC Monograph Drug 9 sections